|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kato H and Nakajima M: Treatments for
esophageal cancer: A review. Gen Thorac Cardiovasc Surg.
61:330–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim T, Grobmyer SR, Smith R, Ben-David K,
Ang D, Vogel SB and Hochwald SN: Esophageal cancer - the five year
survivors. J Surg Oncol. 103:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lordick F, Hölscher AH, Haustermans K and
Wittekind C: Multimodal treatment of esophageal cancer. Langenbecks
Arch Surg. 398:177–187. 2013. View Article : Google Scholar
|
|
6
|
van Hagen P, Hulshof MC, van Lanschot JJB,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al CROSS Group:
Preoperative chemoradiotherapy for esophageal or junctional cancer.
N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heijkoop ST, van Doorn HC, Stalpers LJA,
Boere IA, van der Velden J, Franckena M and Westermann AM: Results
of concurrent chemotherapy and hyperthermia in patients with
recurrent cervical cancer after previous chemoradiation. Int J
Hyperthermia. 30:6–10. 2014. View Article : Google Scholar
|
|
8
|
Gadaleta-Caldarola G, Infusino S, Galise
I, Ranieri G, Vinciarelli G, Fazio V, Divella R, Daniele A,
Filippelli G and Gadaleta CD: Sorafenib and locoregional deep
electro-hyperthermia in advanced hepatocellular carcinoma: A phase
II study. Oncol Lett. 8:1783–1787. 2014.PubMed/NCBI
|
|
9
|
Petryk AA, Giustini AJ, Gottesman RE,
Kaufman PA and Hoopes PJ: Magnetic nanoparticle hyperthermia
enhancement of cisplatin chemotherapy cancer treatment. Int J
Hyperthermia. 29:845–851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Januszewski A and Stebbing J: Hyperthermia
in cancer: Is it coming of age? Lancet Oncol. 15:565–566. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin S, Yang C, Li S, Xu C, Zhao Y and Ren
H: Smac: Its role in apoptosis induction and use in lung cancer
diagnosis and treatment. Cancer Lett. 318:9–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar
|
|
13
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy. Expert Opin Ther Targets.
12:463–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ryan BM, O'Donovan N and Duffy MJ:
Survivin: A new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Or YY, Chow AK, Ng L, Fan ST, Yau TC, Poon
RT and Pang RW: Survivin depletion inhibits tumor growth and
enhances chemosensitivity in hepatocellular carcinoma. Mol Med Rep.
10:2025–2030. 2014.
|
|
16
|
Rice TW: Staging of esophageal cancer: TNM
and beyond. Esophagus. 7:189–195. 2010. View Article : Google Scholar
|
|
17
|
Kanwar JR, Kamalapuram SK and Kanwar RK:
Survivin signaling in clinical oncology: A multifaceted dragon. Med
Res Rev. 33:765–789. 2013. View Article : Google Scholar
|
|
18
|
Coumar MS, Tsai FY, Kanwar JR, Sarvagalla
S and Cheung CH: Treat cancers by targeting Survivin: Just a dream
or future reality? Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Waligórska-Stachura J, Jankowska A, Waśko
R, Liebert W, Biczysko M, Czarnywojtek A, Baszko-Błaszyk D, Shimek
V and Ruchała M: Survivin - prognostic tumor biomarker in human
neoplasms - review. Ginekol Pol. 83:537–540. 2012.
|
|
21
|
Zhao P, Jiang H, Su D, Feng J, Ma S and
Zhu X: Inhibition of cell proliferation by mild hyperthermia at
43°C with Paris Saponin I in the lung adenocarcinoma cell line
PC-9. Mol Med Rep. 11:327–332. 2015.
|
|
22
|
Soares PI, Ferreira IM, Igreja RA, Novo CM
and Borges JP: Application of hyperthermia for cancer treatment:
Recent patents review. Recent Patents Anticancer Drug Discov.
7:64–73. 2012. View Article : Google Scholar
|
|
23
|
Palazzi M, Maluta S, Dall'Oglio S and
Romano M: The role of hyperthermia in the battle against cancer.
Tumori. 96:902–910. 2010.
|
|
24
|
Ahmed K and Zaidi SF: Treating cancer with
heat: Hyperthermia as promising strategy to enhance apoptosis. J
Pak Med Assoc. 63:504–508. 2013.PubMed/NCBI
|
|
25
|
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC,
Hwang JI, Chung CW, Jung YK and Oh BH: An anti-apoptotic protein
human survivin is a direct inhibitor of caspase-3 and -7.
Biochemistry. 40:1117–1123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu D, Liu S, Shi L, Li C, Wu L and Fan Z:
Cleavage of survivin by granzyme M triggers degradation of the
survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to
free caspase activity leading to cytolysis of target tumor cells. J
Biol Chem. 285:18326–18335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koike H, Nitta T, Sekine Y, Arai S, Furuya
Y, Nomura M, Matsui H, Shibata Y, Ito K, Oyama T, et al: YM155
reverses rapamycin resistance in renal cancer by decreasing
Survivin. J Cancer Res Clin Oncol. 140:1705–1713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Winter GE, Radic B, Mayor-Ruiz C, Blomen
VA, Trefzer C, Kandasamy RK, Huber KV, Gridling M, Chen D, Klampfl
T, et al: The solute carrier SLC35F2 enables YM155-mediated DNA
damage toxicity. Nat Chem Biol. 10:768–773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaneko N, Mitsuoka K, Amino N, Yamanaka K,
Kita A, Mori M, Miyoshi S and Kuromitsu S: Combination of YM155, a
survivin suppressant, with bendamustine and rituximab: A new
combination therapy to treat relapsed/refractory diffuse large
B-cell lymphoma. Clin Cancer Res. 20:1814–1822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Talbot DC, Ranson M, Davies J, Lahn M,
Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, et al:
Tumor survivin is downregulated by the antisense oligonucleotide
LY2181308: A proof-of-concept, first-in-human dose study. Clin
Cancer Res. 16:6150–6158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tanioka M, Nokihara H, Yamamoto N, Yamada
Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S,
et al: Phase I study of LY2181308, an antisense oligonucleotide
against survivin, in patients with advanced solid tumors. Cancer
Chemother Pharmacol. 68:505–511. 2011. View Article : Google Scholar
|
